New concepts in the treatment of type 2 diabetes;Neue konzepte in der behandlung des typ-2-diabetes

Internist

Volumn 48, Issue 7, 2007, Pages 698-707

  Meier, J J ^a   Schmidt, W E ^a   Klein, H H ^b  

^a ST JOSEF HOSPITAL   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Diabetes mellitus type 2; Diabetes therapy; DPP 4 inhibitor; Endocannabinoid receptor blockers; GLP 1 analogues incretin mimetics

Indexed keywords

EXENDIN 4; HEMOGLOBIN A1C; RIMONABANT; SITAGLIPTIN; SULFONYLUREA;

BODY WEIGHT; DIABETIC PATIENT; GERMANY; HEALTH INSURANCE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LIPID BLOOD LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; STATISTICAL SIGNIFICANCE; WEIGHT REDUCTION;

ADAMANTANE; ANTIGENS, CD26; BLOOD GLUCOSE; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; NITRILES; PEPTIDES; PIPERIDINES; PYRAZINES; PYRAZOLES; PYRROLIDINES; TRIAZOLES; VENOMS;

EID: 39649084387     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-007-1876-z     Document Type: Review

References (31)

1. Icks A, Rathmann W, Haastert B et al. (2006) [Quality of care and extent of complications in a population-based sample of patients with type 2 diabetes mellitus. The KORA Survey 2000]. Dtsch Med Wochenschr 131: 73-78
2. Creutzfeldt W (1979) The incretin concept today. Diabetologia 16: 75-85
3. Meier JJ, Nauck MA (2005) Glucagon-like peptide 1(GLP-1) in biology and pathology. Diabetes Metab Res Rev 21: 91-117
4. Nauck MA, Baller B, Meier JJ (2004) Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes. Diabetes 53 (Suppl 3): S190-S196
5. Mentlein R, Gallwitz B, Schmidt WE (1993) Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214: 829-835
6. Drucker DJ, Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368: 1696-1705
7. Meier JJ, Gallwitz B, Salmen S et al. (2003) Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 88: 2719-2725
8. Groop LC (1992) Sulfonylureas in NIDDM. Diabetes Care 15: 737-754
9. Nauck MA, Duran S, Kim D et al. (2007) A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 50: 259-267
10. Meier JJ, Gallwitz B, Schmidt WE et al. (2002) Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives. Eur J Pharmacol 440: 269-279
11. Nauck MA, Hompesch M, Filipczak R et al. (2006) Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes 114: 417-423
12. Madsbad S, Schmitz O, Ranstam J et al. (2004) Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): A 12-week, double-blind, randomized, controlled trial. Diabetes Care 27: 1335-1342
13. Meier JJ, Goetze O, Anstipp J et al. (2003) Gastric inhibitory polypeptide (GIP) does not inhibit gastric emptying in man. Am J Physiol (Endocrinol Metab) 284: E931-E939
14. Aschner P, Kipnes M, Lunceford J et al. (2006) Sitagliptin monotherapy improved glycemic control in the fasting and postprandial states and beta-cell function after 24 weeks in patients with type 2 diabetes (T2DM) (abstract 1995-PO). Diabetes 55 (Suppl 1): A 462
15. Raz I, Hanefeld M, Xu L et al. (2006) Sitagliptin monotherapy improved glycemic control and beta-cell function after 18 weeks in patients with type 2 diabetes (T2DM) (abstract 1996-PO). Diabetes 55 (Suppl 1): A 462
16. Charbonnel B, Karasik A, Liu J et al. (2006) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 29: 2638-2643
17. Rosenstock J, Brazg R, Andryuk PJ et al. (2006) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 28: 1556-1568
18. Pi-Sunyer FX, Schweizer A, Mills D et al. (2007) Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract 76: 132-138
19. Bosi E, Camisasca RP, Collober C et al. (2007) Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 30: 890-895
20. Rosenstock J, Baron MA, Dejager S et al. (2007) Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 30: 217-223
21. Meier JJ, Bhushan A, Butler PC (2006) The potential for stem cell therapy in diabetes. Pediatr Res 59: 65R-73R
22. Meier JJ, Nauck MA (2004) GIP as a potential therapeutic agent? Horm Metab Res 36: 859-866
23. Pagotto U, Marsicano G, Cota D et al. (2006) The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 27: 73-100
24. Pi-Sunyer FX, Aronne LJ, Heshmati HM et al. (2006) Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295: 761-775
25. Scheen AJ, Finer N, Hollander P et al. (2006) Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 368: 1660-1672
26. Despres JP, Golay A, Sjostrom L (2005) Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353: 2121-2134
27. Ryan GJ, Jobe LJ, Martin R (2005) Pramlintide in the treatment of type 1 and type 2 diabetes mellitus. Clin Ther 27: 1500-1512
28. Madsen P, Knudsen LB, Wiberg FC et al. (1998) Discovery and structure-activity relationship of the first non-peptide competitive human glucagon receptor antagonists. J Med Chem 41: 5150-5157
29. Ahmed I, Furlong K, Flood J et al. (2007) Dual PPAR alpha/gamma agonists: promises and pitfalls in type 2 diabetes. Am J Ther 14: 49-62
30. Aiello LP, Davis MD, Girach A et al. (2006) Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology 113: 2221-2230
31. Meier JJ, Nauck MA (2005) GLP-1 and its analogues: new ways in the treatment of type 2 diabetes. Curr Med Chem Immun Endoc Metab Agents 5: 485-497